financetom
Business
financetom
/
Business
/
Update: XPeng Shares Rise After Q1 Non-GAAP Loss Narrows, Revenue Increases
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: XPeng Shares Rise After Q1 Non-GAAP Loss Narrows, Revenue Increases
May 21, 2024 7:32 AM

10:14 AM EDT, 05/21/2024 (MT Newswires) -- (Updates with the latest stock price movement in the headline and first paragraph.)

XPeng ( XPEV ) shares were up nearly 13% in recent Tuesday trading after the company's Q1 non-GAAP loss narrowed year-over-year while revenue rose.

The company reported a Q1 non-GAAP net loss of 1.49 Chinese renminbi ($0.21) per diluted American depositary share, narrowing from the non-GAAP net loss of 2.57 renminbi per ADS a year earlier.

Three analysts polled by Capital IQ expected a non-GAAP net loss of 1.77 renminbi per ADS.

Revenue for the quarter ended March 31 was 6.55 billion renminbi, up from 4.03 billion renminbi a year earlier.

Four analysts polled by Capital IQ expected 6.41 billion renminbi.

The company said it expects Q2 revenue of 7.5 billion renminbi to 8.3 billion renminbi. Analysts polled by Capital IQ expect 10.65 billion renminbi.

Price: 9.35, Change: +1.07, Percent Change: +12.91

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
EXPLAINER-Why is leucovorin being considered as an autism treatment?
EXPLAINER-Why is leucovorin being considered as an autism treatment?
Sep 23, 2025
(Adds detail about GSK in paragraph 3) By Nancy Lapid Sept 23 (Reuters) - On Monday, the U.S. Food and Drug Administration published a notice to the Federal Register ahead of a speech by President Donald Trump, approving a version of leucovorin made by GlaxoSmithKline that the company had previously withdrawn from the FDA's consideration when it stopped manufacturing the...
Rocket Lab Insider Sold Shares Worth $41,985,316, According to a Recent SEC Filing
Rocket Lab Insider Sold Shares Worth $41,985,316, According to a Recent SEC Filing
Sep 23, 2025
03:38 AM EDT, 09/23/2025 (MT Newswires) -- Adam C. Spice, Chief Financial Officer, on September 18, 2025, sold 874,588 shares in Rocket Lab ( RKLB ) for $41,985,316. Following the Form 4 filing with the SEC, Spice has control over a total of 2,057,889 common shares of the company, with 2,057,889 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1819994/000200101125000080/xslF345X05/edgardoc.xml ...
AvePoint Insider Sold Shares Worth $31,468,973, According to a Recent SEC Filing
AvePoint Insider Sold Shares Worth $31,468,973, According to a Recent SEC Filing
Sep 23, 2025
03:43 AM EDT, 09/23/2025 (MT Newswires) -- Tianyi Jiang, Director, Chief Executive Officer, on September 18, 2025, sold 2,068,966 shares in AvePoint ( AVPT ) for $31,468,973. Following the Form 4 filing with the SEC, Jiang has control over a total of 13,841,853 common shares of the company, with 13,841,853 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1777921/000143774925029638/xslF345X05/rdgdoc.xml ...
AvePoint Insider Sold Shares Worth $3,285,360, According to a Recent SEC Filing
AvePoint Insider Sold Shares Worth $3,285,360, According to a Recent SEC Filing
Sep 23, 2025
03:42 AM EDT, 09/23/2025 (MT Newswires) -- James Caci, Chief Financial Officer, on September 18, 2025, sold 216,000 shares in AvePoint ( AVPT ) for $3,285,360. Following the Form 4 filing with the SEC, Caci has control over a total of 213,030 common shares of the company, with 213,030 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1777921/000143774925029637/xslF345X05/rdgdoc.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved